

## Data Sharing Statement

|                     |   |   |
|---------------------|---|---|
| <b>Article Info</b> | <a href="https://dx.doi.org/10.21037/tlcr-23-449">https://dx.doi.org/10.21037/tlcr-23-449</a>   |   |
| <b>Item</b>         | <b>Question</b>   | <b>Authors' Response<br/>(place "-" if not applicable)</b>  |
| 1                   | Would you like to share data collected for your study to others?  | Yes   |
| 2                   | If not, would you like to share the reason for your decision?   |   |
| 3                   | What data in particular will be shared?   | The survival data will be shared.   |
| 4                   | Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Study protocol and statistical analysis plan will also be shared if requested.  |
| 5                   | When will data availability begin?  | From the publication date.  |
| 6                   | When will data availability end?  | Two years within the publication date   |
| 7                   | To whom will you share the data?  | Medical oncologists and respiratory physicians interested in studying non-small cell lung cancer with KRAS mutations. |
| 8                   | For what type of analysis or purpose?   | Treatment options for studying KRAS mutated non-small cell lung cancer patients.                                      |
| 9                   | How or where can the data/documents be obtained?  | Emails could be sent to the address below to obtain the shared data: qsy129@fmmu.edu.cn                               |
| 10                  | Any other restrictions?   | We may balance the potential benefits and risks for each request and then provide the data that could be shared.      |